Warnex Inc.

Warnex Inc.

January 16, 2007 07:00 ET

First Trimester Prenatal Screening Recommended by ACOG for all Pregnant Women

LAVAL, QC, Jan. 16 - Warnex Inc. (TSX:WNX) today announced that a
new guideline has been released by the American College of Obstetricians and
Gynecologists (ACOG) stating that all pregnant women, regardless of their age,
should be offered screening for Down syndrome. The new guideline, published in
the January 2007 issue of the journal Obstetrics & Gynecology, also recommends
first trimester screening using both an ultrasound exam that measures nuchal
translucency and a blood test. Warnex's non-invasive Prenatest® prenatal
screening test enables women of any age to measure the risk of Down syndrome
in the first trimester.

"With the trend of the rising age of expectant mothers, Warnex offers the
best non-invasive solution for prenatal screening in the first trimester,"
said Dr. Yvan Côté, Vice President and General Manager of Warnex Medical
Laboratories. "The Prenatest prenatal screening test, which poses no threat to
the mother or the foetus, is highly specific and sensitive in determining the
risk of a birth anomaly, such as Down syndrome."

Down syndrome, also known as trisomy 21, is a genetic disorder in which
the foetus receives three copies of chromosome 21, rather than two. This
disorder gives rise to intellectual and physical handicaps (including cardiac
disorders) for which it is impossible to predict the degree of severity.
According to the Canadian Down Syndrome Society, Down syndrome occurs in about
1 in 700 births, but the incidence rate increases significantly with the age
of the mother. However, since 80% of babies born with Down syndrome are from
mothers aged 35 years and under, prenatal screening is recommended for women
of all ages.

The Prenatest prenatal screening test, performed in the first trimester,
informs a pregnant woman on the risk of her foetus being affected by a common
birth anomaly, such as Down syndrome, trisomy 18 and trisomy 13. The Prenatest
method combines maternal blood protein measurements with the ultrasound
measurements of the fluid accumulation behind the neck of the foetus (nuchal
translucency) and, if possible, the presence of the nasal bone. It is the
earliest and most effective Down syndrome screening test available. The blood
analysis, combined with nuchal translucency and nasal bone ultrasound
measurements, yields a detection rate of 95% and a false positive rate of 2%
when the test is carried out during the first trimester.

For more information on the Prenatest prenatal screening test, visit
www.prenatest.ca.

About Warnex

Warnex (www.warnex.ca) is a biotechnology company devoted to protecting
public health by providing advanced diagnostic products and science-based
services to the agri-food, pharmaceutical and healthcare sectors. Warnex's
DNA-based technology offers a versatile detection platform that produces
accurate results rapidly, using Real-Time PCR technology combined with unique
genetic markers and software. With a focus on pathogen detection in food, our
development pipeline also includes applications in GMO testing and meat
speciation, as well as in the detection of viruses, yeasts and moulds.
Warnex's analytical, bioanalytical, and medical laboratory service groups
offer a variety of quality control services, method development and
validation, contract R&D, bioavailability and bioequivalence studies for
clinical trials, and medical laboratory testing.

Prenatest is a registered trademark of Warnex Inc., Laval, Quebec.

CAUTION REGARDING FORWARD-LOOKING STATEMENTS

Certain statements contained in this news release are forward-looking and
are subject to numerous risks and uncertainties, known and unknown. For
information identifying known risks and uncertainties, relating to the early
commercialization of Warnex products, intellectual property and licensing, R&D
of new Warnex products, integration of acquisitions, manufacturing and
laboratory facilities, suppliers, key employees, key customers and business
partners, financial resources and credit risk, government regulations, foreign
currency risk and volatility of share price, and other important factors that
could cause actual results to differ materially from those anticipated in the
forward-looking statements, please refer to the heading Risks and
Uncertainties in the Management's Discussion and Analysis for the third
quarter ended September 30, 2006, which can be found at www.sedar.com.
Consequently, actual results may differ materially from the anticipated
results expressed in these forward-looking statements.

Contact Information

  • Mark J. Busgang, President & CEO, Warnex Inc.,
    Tel: (450) 663-6724 x.310, mbusgang@warnex.ca; Dr. Yvan Côté, Vice President &
    General Manager, Warnex Medical Laboratories, Tel: (450) 663-6724 x.380,
    ycote@warnex.ca; Mike Polonsky, Investor Relations, The Equicom Group Inc.,
    Tel: (416) 815-0700 x.231, mpolonsky@equicomgroup.com